EGFR-Mutated NSCLC: Integrating Emerging ELCC Data Into Treatment Sequencing

In this segment, Dr. Sands asks the panel to reflect on how emerging data presented at recent meetings, including ELCC, are influencing treatment strategies in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper discuss how subgroup analyses from recent trials, as well as studies in higher-risk molecular populations such as those with TP53 co-mutations, are helping refine treatment selection. They note that these data provide additional insight into which patients may derive greater benefit from combination approaches versus monotherapy. The panel also highlights exploratory findings on chemotherapy rechallenge following progression on prior combination therapy, emphasizing the growing complexity of sequencing decisions. Importantly, they stress that while these data are informative, many remain exploratory and must be interpreted cautiously within the broader clinical context. Overall, this discussion underscores how emerging evidence is beginning to shape more personalized and nuanced treatment sequencing strategies in EGFR-mutated NSCLC.